Cargando…
The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori: Erratum
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837814/ https://www.ncbi.nlm.nih.gov/pubmed/33546089 http://dx.doi.org/10.1097/MD.0000000000024431 |
Ejemplares similares
-
The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori
por: Lee, Seung Woo, et al.
Publicado: (2020) -
Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022) -
Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections
por: Ahn, Hyo Jun, et al.
Publicado: (2017) -
High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea
por: Kwack, WonGun, et al.
Publicado: (2016) -
Erratum to “Epidemiological and Clinical-Pathological Aspects of Helicobacter pylori Infection in Brazilian Children and Adults”
por: Toscano, Evelyn Pedroso, et al.
Publicado: (2019)